Trial Profile
A Randomised, Double-blind, Dose Finding, Repeat Dose Phase II Multicentre Study of ODX for the Treatment of Patients With Castration Resistant Prostate Cancer (CRPC) and Skeletal Metastases
Status:
Active, no longer recruiting
Phase of Trial:
Phase II
Latest Information Update: 27 Jan 2023
Price :
$35
*
At a glance
- Drugs Alendronic acid/guanidine dextran conjugate (Primary)
- Indications Bone metastases
- Focus Biomarker; Therapeutic Use
- Sponsors DexTech Medical
- 20 Dec 2022 Results published in the European Journal of Cancer
- 30 Jul 2020 This trial is completed in Latvia according to European Clinical Trials Database record.
- 13 Jul 2020 This trial is completed in Estonia and Finland (Global End Date: 29 Apr 2020), according to European Clinical Trials Database record.